Clinical Trial Update: Efficacy and Safety Study of Nicotine Mint Lozenge (2mg and 4mg) in Smoking Cessation [Phase 3]

View source ↗

Summary

Phase 3 results from a study of nicotine mint lozenges (2 mg and 4 mg) evaluating efficacy and safety in aiding smoking cessation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nicotine Dependence
• Tobacco Use Disorder

Drugs mentioned

• Nicotine Mint Lozenge 2 mg (nicotine lozenge)
• Nicotine Mint Lozenge 4 mg (nicotine lozenge)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Smoking | Phase 3 | Status: COMPLETED | Results posted: 2014-06-16